See the latest news and media coverage for J&J. We track all announcements, press releases, and industry mentions in real time, all in one place.
Multinational healthcare company
jnj.comLast updated
In short: J&J expanded its oncology and vision portfolios through billion-dollar investments and acquisitions while facing mixed outcomes in talc litigation.
The investment includes new manufacturing and packaging technologies and a state-of-the-art distribution center to scale U.S. Vision operations, enhancing supply chain resilience for over 40 million patients.
Phase 3 MonumenTAL-3 shows up to 72% reduction in progression or death, with 24-month PFS up to 81% and OS up to 89%.
The Phase 2/3 ENERGY trial met primary endpoint with rapid onset. No FDA-approved therapies exist for this condition.
The $1 billion cash deal adds a novel degrader antibody conjugate platform targeting KRAS-driven tumors.
CEO Joaquin Duato says J&J will focus on cancer and other serious diseases instead of obesity drugs.
Johnson Johnson cancer treatment strategy advanced this week as Phase 3 MonumenTAL-3 data showed TALVEY cuts myeloma death risk 53%, while a $1B bet on...
A Minnesota state judge on Monday upheld a $65.5 million verdict awarded to a mother of three children who had claimed that Johnson & Johnson's...
Johnson & Johnson (JNJ) spent 2025 proving it could lose a multibillion-dollar drug and still grow. On June 13, the company reported results from a...
Track J&J and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to J&J and other trending companies.